Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies

被引：4
|
作者：
Gressens, Simon B. [1 ]
Wiedemann, Aurelie [2 ,4 ]
Dechenaud, Marie [2 ]
Dupuis, Jehan [3 ]
Gallien, Sebastien [1 ,4 ]
Melica, Giovanna [1 ,4 ]
Haioun, Corinne [3 ,4 ]
Lemonnier, Francois [3 ,4 ]
Levy, Yves [1 ,2 ]
机构：
[1] Univ Paris Est Creteil, Hop Univ Henri Mondor, AP HP, Infect Dis & Immunol Dept, Creteil, France
[2] Univ Paris Est Creteil, Vaccine Res Inst, Fac Med, Team 16,INSERM U955, Creteil, France
[3] Grp Hosp Univ Chenevier Mondor, Serv Unite Hemopathies Lymphoides, IAP HP, F-94010 Creteil, France
[4] Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France
来源：
VACCINE | 2023年 / 41卷 / 09期
关键词：
Third dose; COVID-19; Immunocompromised; Vaccine; T cell responses; Hematological malignancies; SARS-COV-2; IMMUNITY;
D O I：
10.1016/j.vaccine.2023.01.064
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vac-cine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 ther-apies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4+Th1+T cell responses while the effect CD8 + T cell responses was marginal. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1550 / 1553
页数：4
相关论文
共 50 条
  • [41] The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2
    Marchesi, Francesco
    Pimpinelli, Fulvia
    Sperandio, Eleonora
    Papa, Elena
    Falcucci, Paolo
    Pontone, Martina
    di Martino, Simona
    de Latouliere, Luisa
    Orlandi, Giulia
    Morrone, Aldo
    Ciliberto, Gennaro
    Mengarelli, Andrea
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (02) : 362 - 367
  • [42] Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies
    Philippe Nicolas
    Hugo Marion-Moffet
    Morgane Gossez
    Sandra Vukusic
    Guillaume Monneret
    Romain Marignier
    Fabienne Venet
    Journal of Neurology, 2023, 270 : 32 - 36
  • [43] Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies
    Nicolas, Philippe
    Marion-Moffet, Hugo
    Gossez, Morgane
    Vukusic, Sandra
    Monneret, Guillaume
    Marignier, Romain
    Venet, Fabienne
    JOURNAL OF NEUROLOGY, 2023, 270 (01) : 32 - 36
  • [44] SEROLOGICAL RESPONSE TO BNT162B2 MRNA ANTI-SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: RESULTS FROM THE RHEUVAX COHORT
    Mauro, D.
    Ciancio, A.
    Di Vico, C.
    Passariello, L.
    Rozza, G.
    Pasquale, M. D.
    Pantano, I.
    Bucci, L.
    Cannista, C.
    Scriffignano, S.
    Riccio, F.
    Patrone, M.
    Scalise, G.
    Vietri, M. T.
    Ciccia, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 934 - 934
  • [45] Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
    Milena Cavic
    Andrijana Nesic
    Katarina Mirjacic Martinovic
    Ana Vuletic
    Irina Besu Zizak
    Nevena Tisma Miletic
    Ana Krivokuca
    Radmila Jankovic
    Marija Gavrovic-Jankulovic
    Scientific Reports, 13
  • [46] SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents
    Fenioux, Charlotte
    Teixeira, Luis
    Fourati, Slim
    Melica, Giovanna
    Lelievre, Jean Daniel
    Gallien, Sebastien
    Zalcman, Gerard
    Pawlotsky, Jean Michel
    Tournigand, Christophe
    JAMA ONCOLOGY, 2022, 8 (04) : 612 - 617
  • [47] Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
    Saresella, Marina
    Piancone, Federica
    Marventano, Ivana
    Hernis, Ambra
    Trabattoni, Daria
    Invernizzi, Mattia
    La Rosa, Francesca
    Clerici, Mario
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease
    Stercel, Vivien
    Loczi, Linda
    Kadenczki, Orsolya
    Nemes, Eva
    Nagy, Bela
    Hodossy-Takacs, Rebeka
    Szabo, Attila adam
    Fagyas, Miklos
    Kappelmayer, Janos
    Szabo, Tamas
    Bagoly, Zsuzsa
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [49] Anti-SARS-CoV-2 Spike Antibody Response to the Fourth Dose of BNT162b2 mRNA COVID-19 Vaccine and Associated Factors in Japanese Hemodialysis Patients
    Hirai, Keiji
    Shimotashiro, Masako
    Okumura, Toshiaki
    Ookawara, Susumu
    Morishita, Yoshiyuki
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2024, 17 : 135 - 149
  • [50] Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
    Hirai, Keiji
    Shimotashiro, Masako
    Okumura, Toshiaki
    Ookawara, Susumu
    Morishita, Yoshiyuki
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2024, 43 (03) : 326 - 336
12345